Here are what the editors at HealthDay consider to be the most important developments in Pharmacy for September 2020. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that are the most likely to affect clinical practice.
Review IDs Dietary Factors Linked to Lower CRC Incidence
WEDNESDAY, Sept. 30, 2020 (HealthDay News) — Decreased colorectal cancer (CRC) incidence is seen in association with use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), magnesium, folate, and high consumption of fruits and vegetables, fiber, and dairy products, according to an umbrella review published online Sept. 28 in Gut.
U.S. Government to Ship Millions of Rapid COVID-19 Tests This Week
TUESDAY, Sept. 29, 2020 (HealthDay News) — The U.S. government will start distributing millions of rapid COVID-19 tests to states this week with the goal of reopening schools.
Global Death Toll From COVID-19 Passes 1 Million
TUESDAY, Sept. 29, 2020 (HealthDay News) — The global COVID-19 pandemic reached a grim new milestone on Tuesday: 1 million dead.
AP News Article
Johns Hopkins University
Gabapentin Does Not Lower Pain Scores in Chronic Pelvic Pain
TUESDAY, Sept. 29, 2020 (HealthDay News) — For women with chronic pelvic pain, gabapentin treatment does not result in significantly lower pain scores and is associated with more side effects than placebo, according to a study published online Sept. 26 in The Lancet.
Proton Pump Inhibitor Use Linked to Increased T2DM Risk
TUESDAY, Sept. 29, 2020 (HealthDay News) — Regular use of proton pump inhibitors (PPIs) is associated with an increased risk for type 2 diabetes, according to a study published online Sept. 28 in Gut.
Lockdown Tied to Worsening of Musculoskeletal Conditions
TUESDAY, Sept. 29, 2020 (HealthDay News) — Early stages of the U.K. COVID-19 lockdown had negative consequences for people with musculoskeletal conditions, according to a letter to the editor published online Sept. 22 in Rheumatology: Advances in Practice.
Abstract/Full Text (subscription or payment may be required)
New FDA Applications for Opioids Often Based on Short Trials
TUESDAY, Sept. 29, 2020 (HealthDay News) — New drug applications (NDAs) for prescription opioids for pain have been based on pivotal trials of short or intermediate duration, often in narrowly defined pain populations, according to a study published online Sept. 29 in the Annals of Internal Medicine.
Abstract/Full Text (subscription or payment may be required)
Private Health Plans Pay Hospitals 247 Percent of Medicare
MONDAY, Sept. 28, 2020 (HealthDay News) — During 2018, prices paid to hospitals by privately insured patients averaged 247 percent of what Medicare would have paid, according to a study from the RAND Corporation.
Hydroxychloroquine Tied to Heart Problems Prior to Pandemic
FDA Warns of Rising Dangers of Unapproved Drug Tianeptine 
2015 to 2019 Saw Downward Trend for Buprenorphine Misuse 
Rahul Gupta to Be Nominated as Next U.S. Drug Czar 
Buprenorphine Rx Activity Varies Widely Among Clinicians 
Pegylated Interferon Lambda Effective in Preventing Severe COVID-19 
Difelikefalin Improves Itch Intensity in Notalgia Paresthetica 
Could a Vibrating Pill Ease Chronic Constipation? 
Mental Health Concerns Increasingly Addressed at Primary Care Visits 
